Wealthquest Corp Takes $59,000 Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Wealthquest Corp acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 2,367 shares of the company’s stock, valued at approximately $59,000.

A number of other large investors have also bought and sold shares of the business. Natixis Advisors LLC bought a new position in Pacira BioSciences during the 1st quarter worth about $327,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Pacira BioSciences by 20.8% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,519 shares of the company’s stock worth $410,000 after buying an additional 2,848 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Pacira BioSciences during the first quarter worth about $392,000. Easterly Investment Partners LLC raised its position in Pacira BioSciences by 6.2% in the 1st quarter. Easterly Investment Partners LLC now owns 112,171 shares of the company’s stock valued at $2,787,000 after buying an additional 6,520 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in Pacira BioSciences by 119.1% in the 1st quarter. Victory Capital Management Inc. now owns 207,555 shares of the company’s stock valued at $5,158,000 after buying an additional 112,805 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Lauren Riker sold 5,578 shares of the firm’s stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total value of $146,199.38. Following the completion of the sale, the senior vice president directly owned 59,564 shares of the company’s stock, valued at $1,561,172.44. This trade represents a 8.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 6.40% of the stock is currently owned by company insiders.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $22.07 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.41 and a quick ratio of 1.99. The firm has a 50-day moving average of $23.83 and a 200-day moving average of $24.55. The company has a market cap of $1.02 billion, a PE ratio of -9.68 and a beta of 0.48. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $27.64.

Wall Street Analyst Weigh In

PCRX has been the subject of a number of recent research reports. Needham & Company LLC reduced their price target on Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Wall Street Zen upgraded shares of Pacira BioSciences from a “hold” rating to a “buy” rating in a report on Friday, June 6th. Truist Financial upgraded shares of Pacira BioSciences from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research note on Friday, July 25th. Finally, HC Wainwright boosted their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Pacira BioSciences has an average rating of “Moderate Buy” and a consensus target price of $25.75.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.